William Robert Thurlby, MD in Dover, AR - Internal Medicine

William Robert Thurlby, MD is a Internal Medicine physician based in Dover, Arkansas. William Robert Thurlby is licensed to practice in Arkansas (license number C-4419) and his current practice location is 8970 Market St, Dover, Arkansas. He can be reached at his office (for appointments etc.) via phone at (479) 331-3880.

NPI number for William Robert Thurlby is 1962468629 and his current mailing address is 8970 Market St, Dover, Arkansas. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1962468629.

Contact Information

	William Robert Thurlby, MD
	8970 Market St, Dover, AR 72837-9110
	(479) 331-3880
	(479) 331-3788

Physician's Profile

Full Name	William Robert Thurlby
Gender	Male
Speciality	Internal Medicine
Location	8970 Market St, Dover, Arkansas
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1962468629
Provider Enumeration Date: 04/21/2006
Last Update Date: 01/14/2015

Medical Identifiers

Medical identifiers for William Robert Thurlby such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1962468629	NPI	-	NPPES
103883001	Medicaid	AR

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207R00000X	Internal Medicine	C-4419 (Arkansas)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. William Robert Thurlby is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
William Robert Thurlby, MD 8970 Market St, Dover, AR 72837-9110 Ph: (479) 331-3880	William Robert Thurlby, MD 8970 Market St, Dover, AR 72837-9110 Ph: (479) 331-3880

News Archive

Researchers examine potential SARS-CoV-2 antivirals using a drug repurposing library

A new study deals with the screening of the Drug Repurposing Hub (DRH) library for identifying small compounds which are capable of inhibiting SARS-CoV-2 using both in vitro and in vivo experimental studies. These molecules could be used for designing a novel therapeutic system against SARS-CoV-2 infection.

Oral dabigatran etexilate reduces the risk of stroke and systemic embolism

Boehringer Ingelheim today announced data from the landmark RE-LY® study - the largest atrial fibrillation (AF) outcomes trial ever conducted (18,113 patients in 44 countries worldwide) - presented for the first time at the European Society of Cardiology Congress and published online in the New England Journal of Medicine. Results show that dabigatran etexilate 150mg BID significantly reduces the risk of stroke and systemic embolism by 34% (p<0.001) in patients with atrial fibrillation compared to well-controlled warfarin without increasing the risk of major bleeding.

Study shows feasibility of home monitoring to detect heart arrhythmias in developing fetuses

As reported in the Journal of Perinatology, researchers from Children's Hospital Colorado (Children's Colorado) recently confirmed that it is feasible for at-risk pregnant women to use commercially-available Doppler fetal heart rate monitors for home monitoring to detect heart arrhythmias in their developing fetuses.

CMS allows doctors to drop Medicare participation agreement until Feb. 14

The Centers for Medicare and Medicaid Services (CMS) has announced the unprecedented step of allowing doctors until Feb. 14 to drop their Medicare participation agreement and become a "non-participating" physician. Usually, doctors have to make that change before the end of a calendar year.

William Robert Thurlby, MD - Internal Medicine in Dover, AR